Trial Profile
Efficacy and safety of Ipragliflozin in patient with type 2 diabetes who have inadequate glycemic control.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
- 06 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 21 Oct 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.